Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Abecma“
Suchtreffer
Begriffe & Kennungen
Abecma · 4.8 · 16 Neurotoxicity identified by the investigators, which was the primary method of assessing CAR T cell associa
Eintrag öffnenAbecma · 4.8 · 17 Reporting of suspected adverse reactions
Eintrag öffnenAbecma · 4.8 · Abecma has the potential to induce anti-CAR antibodies. In clinical studies, humoral immunogenicity of Abecma
Eintrag öffnenAbecma · 4.8 · Cytokine release syndrome In the pooled studies (KarMMa, CRB-401 and KarMMa-3), CRS occurred in 84.6% of patie
Eintrag öffnenAbecma · 4.8 · Description of selected adverse reactions
Eintrag öffnenAbecma · 4.8 · Febrile neutropenia (Grade 3 or 4) was observed in 10.8% of patients after Abecma infusion. Febrile neutropeni
Eintrag öffnenAbecma · 4.8 · Febrile neutropenia and infections In the pooled studies, infections occurred in 62.8% of patients. Grade 3 or
Eintrag öffnenAbecma · 4.8 · Grade 3 or 4 adverse reactions were more often observed within the initial 8 weeks post-infusion (93.2%) compa
Eintrag öffnenAbecma · 4.8 · Hypogammaglobulinaemia Hypogammaglobulinaemia was reported in 13.7% of patients treated with Abecma in the poo
Eintrag öffnenAbecma · 4.8 · Immunogenicity
Eintrag öffnenAbecma · 4.8 · In KarMMa, across the target dose levels, 7.8% of patients received at least 1 dose of corticosteroid for trea
Eintrag öffnenAbecma · 4.8 · In KarMMa-3, across all patients who received Abecma infusion at the target dose range, 6.7% of patients recei
Eintrag öffnenAbecma · 4.8 · Neurologic adverse reactions including ICANS In the pooled studies, of the 409 patients, independent of invest
Eintrag öffnenAbecma · 4.8 · Of the 353 patients in the KarMMa and KarMMa-3 studies, the most common manifestations of investigator identif
Eintrag öffnenAbecma · 4.8 · Of the 409 patients, 59.7% of patients received tocilizumab; 37.2% received a single dose while 22.5% received
Eintrag öffnenAbecma · 4.8 · Prolonged cytopenia Patients may exhibit prolonged cytopenias following lymphodepleting chemotherapy and Abecm
Eintrag öffnenAbecma · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenAbecma · 4.8 · Serious adverse reactions occurred in 57.2% of patients. The most common serious adverse reactions (≥ 5%) incl
Eintrag öffnenAbecma · 4.8 · Summary of the safety profile
Eintrag öffnenAbecma · 4.8 · System organ class Adverse reaction All grades frequency Infections and Infections – bacterial Very common inf
Eintrag öffnen